Bioptix
Castle Rock
About Bioptix
Venaxis is a Colorado-based in vitro diagnostic company focused on developing and commercializing its unique multi-biomarker diagnostic test, the APPY1 Test. Designed to aid in the identification of patients at low risk for acute appendicitis, the APPY1 Test is a simple, rapid blood test that may help physicians manage the large number of children and adolescents who enter hospital emergency departments with abdominal pain, suspected of acute appendicitis. Determining whether a patient requires emergency surgery for appendicitis is critical and current practices have important limitations.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $18.4M
- Funding stage: M&A
- Last round: Post-IPO Equity (Apr 2014)
- Ticker: nasdaq:BIOP
- Website: venaxis.com
- Phone: 13037988332
Industries & Categories
Health Care, Health Diagnostics, Therapeutics
Canonical: https://fsome.com/organization/bioptix-1494542 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.